Skip to main content

Table 1. Twenty-seven reported cases of IFN-α-induced sarcoidosis [5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28].

From: Interferon-induced sarcoidosis with uveitis as the initial symptom: a case report and review of the literature

  

Patients (n)

Proportion of patients (%)

Primary diseases

Chronic hepatitis C

24

88.9

 

Melanoma

2

7.4

 

Erythrocytosis

1

3.7

Sex

Male

12

44.4

 

Female

15

55.6

Age of sarcoidosis onset

(mean ± standard deviation)

Overall: 51.4 ± 10.8 years

Men: 48.3 ± 9.9 years

Women: 53.9 ± 11.1 years

Treatment

IFN-α + ribavirin

21

77.8

 

IFN-α

4

14.8

 

IFN-α + ribavirin + others

2

7.4

Period until onset

7.9 months (n = 24)

(range, 2–14 months)

Organ involvement

Skin

23

85.1

 

Lung*

19

70.1

 

Lymphadenopathy (mediastinal)

11

40.7

 

Lymphadenopathy (hilar)

11

40.7

 

Lymphadenopathy (axillary)

11

40.7

 

Eye

4

14.8

 

Other (heart, liver, central nervous system, retroperitoneal lymphadenopathy, stomach, thyroid)

3

Each 1

11.1

Each 3.7

Therapy

Discontinuation of IFN

16

59.2

 

Continuation of IFN

2

25.9

 

Already completed IFN treatment

2

7.4

 

Unknown

2

7.4

 

Topical steroid

10

37.0

 

Oral steroid

8

29.6

 

Steroid pulse

2

7.4

 

Others (permanent cardiac pacemaker)

1

3.7

Outcome

Resolution

15

55.6

 

Improvement

8

29.6

 

No change

2

7.4

 

Death

1

3.7

 

Unknown

1

3.7

  1. IFN interferon, n number
  2. * with or without mediastinal and/or hilar lymphadenopathy